DORNASE ALFA IN RUSSIA: 15 YEARS LATER. EFFICACY OF THE DRUG IN THE BASIC TREATMENT IN CHILDREN WITH CYSTIC FIBROSIS

DORNASE ALFA IN RUSSIA: 15 YEARS LATER. EFFICACY OF THE DRUG IN THE BASIC TREATMENT IN CHILDREN WITH CYSTIC FIBROSIS

The 15-years practice of Pulmozyme (dornase alfa) usage showed its high efficacy and safety in cystic fibrosis treatment in children of various age, including infants. The efficacy of the drug is associate with clinical effects: strong mucolytic, anti-inflammatory and antibacterial effects. The appr...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. I. Simonova, O. F. Lukina
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2012-03-01
Series:	Вопросы современной педиатрии
Subjects:	cystic fibrosis dornase alfa children mucostasis chronic non-specific lung diseases chronic polypous pansinusitis cystic fibrosis basic treatment
Online Access:	https://vsp.spr-journal.ru/jour/article/view/133
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Trends in Life Expectancy of Cystic Fibrosis Patients in Moscow and their Connection with the Treatment Received: Retrospective Analysis for 1993–2013
by: N. Yu. Kashirskaya, et al.
Published: (2015-09-01)

INFLUENCE OF THE AGE OF THE DIAGNOSIS AND THE BEGINNING OF SPECIFIC THERAPY ON MAIN CLINICAL AND LABORATORY MANIFESTATIONS OF A DISEASE IN PATIENTS WITH CYSTIC FIBROSIS
by: S. A. Krasovskii, et al.
Published: (2014-03-01)

THE NATIONAL CONSENSUS PROJECT* «CYSTIC FIBROSIS: DEFINITION, DIAGNOSTIC CRITERIA, AND THERAPY». SECTION «INHALATION THERAPY» (ABRIDGED)
by: Ye. L. Amelina, et al.
Published: (2014-12-01)

Current Status of Cystic Fibrosis in Türkiye: Data from the National Registry
by: Dilber Ademhan Tural, et al.
Published: (2025-09-01)

Quantitative ultrasound rating of liver fibrosis in children with cystic fibrosis
by: G. M. Dvoryakovskaya, et al.
Published: (2014-08-01)

Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis
by: Jaime L. Rubin, et al.
Published: (2025-07-01)

ROLE OF THE KNOWN MUCOLYTICS IN MUCOVISCIDOSIS THERAPY
by: O. I. Simonova, et al.
Published: (2014-11-01)

Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
by: Nemirajaiah, S.
Published: (2021-08-01)

A descriptive cohort study of pregnancy and parenthood in women with cystic fibrosis
by: Aleksandra Duffy, et al.
Published: (2025-07-01)

Translation, cross-cultural adaptation, and evaluation of psychometric properties of the cystic fibrosis stigma scale
by: Victor Hugo Brito de Oliveira¹, et al.
Published: (2025-05-01)

Pulmonary Aspergillosis in Patients with Cystic Fibrosis in Russian Federation
by: Ya. I. Kozlova, et al.
Published: (2018-07-01)

Clinicopathologic Features of Kidney Disease in Patients With Cystic Fibrosis
by: Tiffany N. Caza, et al.
Published: (2024-07-01)

Results of an observational study of the safety of antimicrobial scratching in 15 children with cystic fibrosis at the inpatient stage of treatment at the State Budgetary Healthcare Institution “Morozovskaya Children’s City Clinical Hospital of Moscow Healthcare Department” from 12.12.2019 to 30.03.2020
by: A. V. Vlasova, et al.
Published: (2020-03-01)

Ultrasonographic assessment of diaphragmatic excursion and its correlation with pulmonary function tests in pediatric cystic fibrosis
by: Eman Mahmoud Fouda, et al.
Published: (2025-07-01)

Mapping the oxidative landscape in cystic fibrosis: methodological frontiers and application
by: Michela Rubin, et al.
Published: (2025-07-01)

Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
by: Burkhard Tümmler, et al.
Published: (2025-05-01)

Hypercubes to identify geomarkers of rapid cystic fibrosis lung disease progression
by: Yizi Cheng, et al.
Published: (2025-08-01)

Lung function trajectories in children with early diagnosis of non-cystic fibrosis bronchiectasis: a retrospective observational study
by: Rossella Lamberti, et al.
Published: (2024-11-01)

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction
by: Alice Castaldo, et al.
Published: (2025-07-01)

Effectiveness of photodynamic therapy of a patient with early central lung cancer and cystic fibrosis
by: E. S. Borzenko, et al.
Published: (2019-10-01)

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
by: Steven J Edwards, et al.
Published: (2025-05-01)

DETERMINATION OF SOME COMPONENTS OF THE DENTAL STATUS OF CHILDREN WITH CYSTIC FIBROSIS
by: R. S. Nazarian, et al.
Published: (2018-03-01)

Targeting the MEK1/2 pathway to combat Staphylococcus aureus infection and inflammation in cystic fibrosis
by: Eryn Zuiker, et al.
Published: (2025-07-01)

Key International Instruments for Assessing the Quality of Life in Patients with Cystic Fibrosis: Comparative Properties and Characteristics
by: D. A. Andreev
Published: (2025-03-01)

A severe early presentation of cystic fibrosis in an infant with a homozygous c.1375_1383del CFTR variant- a case report
by: Abdullah Yousef, et al.
Published: (2025-08-01)

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis
by: Wang Shin Lei, et al.
Published: (2025-06-01)

SMALL INTESTINAL BACTERIAL OVERGROWTH IN PEOPLE WITH CYSTIC FIBROSIS: SYSTEMATIC REVIEW
by: Maria Lidiane Lavor LANDIM, et al.
Published: (2025-05-01)

Heterogeneity of phenotypic manifestations of cystic fibrosis in children and predictors of the disease severity
by: K. V. Skriabina, et al.
Published: (2022-12-01)

Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor
by: Espérie Burnet, et al.
Published: (2025-09-01)

Uptake of genetic counselling services by patients with cystic fibrosis and their families
by: S. Macaulay, et al.
Published: (2012-06-01)

Respiratory system parameters and clinical markers in children with cystic fibrosis
by: Tayná Castilho, et al.
Published: (2025-08-01)

Survival Outcomes in US Medicare Patients with Non-Cystic Fibrosis Bronchiectasis by Rate of Baseline Exacerbations
by: Joseph Feliciano, et al.
Published: (2024-10-01)

The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development
by: D. A. Blagovidov, et al.
Published: (2016-04-01)

Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies
by: Guillermo García-Pérez-de-Sevilla, et al.
Published: (2025-07-01)

Clinical Significance of Lung Microbiota and Experience of the Inhaled Antibacterial Therapy in Children of the Omsk Cystic Fibrosis Center (Сase Series)
by: Elena B. Pavlinova, et al.
Published: (2018-05-01)

LUNG TRANSPLANTATION IN CYSTIC FIBROSIS PATIENT WITH CHRONIC AIRWAYS INFECTION OF BURKHOLDERIA CEPACIA (the first case in Russian Federation)
by: S. V. Gautier, et al.
Published: (2016-06-01)

Evaluation of Short-Term Use of Positive and Oscillating Positive Expiratory Pressure in Bronchial Drainage in Cystic Fibrosis Patients During an Exacerbation of The Disease
by: Jarosław Prusak, et al.
Published: (2024-02-01)

Directions of Epidemiological Surveillance of Chronic Lung Infections Caused by <i>Burkholderia cepacia Complex</i>, <i>Achromobacter spp., Pseudomonas aeruginosa</i> and Methicillin-Resistant <i>Staphylococcus aureus</i> in Patients with Cystic Fibrosis
by: L. R. Avetisyan, et al.
Published: (2020-03-01)

The Prevalence of Genetic Determinants of Antibiotic Resistance, which are of Particular Epidemiological Consequences, in the Microbiota of the Oropharyngeal Swabs in Patients with Cystic Fibrosis
by: T. S. Skachkova, et al.
Published: (2023-09-01)

Biofilm Formation of <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis: Mechanisms of Persistence, Adaptation, and Pathogenesis
by: Dayana Borisova, et al.
Published: (2025-06-01)